Protein therapeutics: Volume 2
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim, Germany
Wiley-VCH
[2017]
|
| Schriftenreihe: | Methods and principles in medicinal chemistry
Volume 71b Methods and principles in medicinal chemistry volume 71 |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXI, Seiten 311-717 Illustrationen, Diagramme |
Internformat
MARC
| LEADER | 00000nam a2200000 cc4500 | ||
|---|---|---|---|
| 001 | BV044350036 | ||
| 003 | DE-604 | ||
| 005 | 20180315 | ||
| 007 | t | ||
| 008 | 170614s2017 gw a||| |||| 00||| eng d | ||
| 016 | 7 | |a 1140803662 |2 DE-101 | |
| 035 | |a (OCoLC)1012844540 | ||
| 035 | |a (DE-599)DNB1140803662 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-29 |a DE-11 |a DE-19 | ||
| 084 | |a VK 8560 |0 (DE-625)147540:253 |2 rvk | ||
| 084 | |a VS 7000 |0 (DE-625)147697:253 |2 rvk | ||
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 245 | 1 | 0 | |a Protein therapeutics |n Volume 2 |c edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal |
| 264 | 1 | |a Weinheim, Germany |b Wiley-VCH |c [2017] | |
| 300 | |a XXI, Seiten 311-717 |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Methods and principles in medicinal chemistry |v Volume 71b | |
| 490 | 1 | |a Methods and principles in medicinal chemistry |v volume 71 | |
| 700 | 1 | |a Vaughan, Tristan |4 edt | |
| 700 | 1 | |a Osbourn, Jane |4 edt | |
| 700 | 1 | |a Jallal, Bahija |4 edt | |
| 773 | 0 | 8 | |w (DE-604)BV044349964 |g 2 |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v Volume 71b |w (DE-604)BV035418617 |9 71,2 | |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v volume 71 |w (DE-604)BV035418617 |9 71 | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029752859&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029752859 | ||
Datensatz im Suchindex
| _version_ | 1804177590107242496 |
|---|---|
| adam_text | CONTENTS TO VOLUME 1
PREFACE
X V
A PERSONAL FOREWORD
XIX
ACKNOWLEDGMENTS
XXI
PART I INTRODUCTION TO PROTEIN THERAPEUTICS: PAST AND PRESENT
1
1 EARLY RECOMBINANT PROTEIN THERAPEUTICS
3
PIERRE DE MEYTS
2 EVOLUTION OF ANTIBODY THERAPEUTICS
25
HERVE WOTIER AND JANICE M. REICHERT
PART II ANTIBODIES: THE ULTIMATE SCAFFOLD FOR PROTEIN
THERAPEUTICS
51
3 HUMAN ANTIBODY STRUCTURE AND FUNCTION
53
PONRAJ PRABAKARAN AND DIMITERS. DIMITROV
4 ANTIBODIES FROM OTHER SPECIES
85
MELISSA L VADNAIS, MICHAEL F. CRISCITIELLO, AND VAUGHN V. 5MIDER
PART III DISCOVERY AND ENGINEERING OF PROTEIN THERAPEUTICS
113
5 HUMAN ANTIBODY DISCOVERY PLATFORMS
115
WILLIAM R. STROHL
6 BEYOND ANTIBODIES: ENGINEERED PROTEIN SCAFFOLDS FOR THERAPEUTIC
DEVELOPMENT
161
NISHANT K. MEHTA AND JENNIFER R. COCHRAN
7 PROTEIN ENGINEERING: METHODS AND APPLICATIONS
189
CLAIRE DOBSON AND WILLIAM DALL ACQUA
8 BISPECIFICS
229
JIJIE GU, ANDREW MCCLUSKEY, AND TARIQ GHAYUR
9 ANTIBODY-DRUG CONJUGATES (ADCS)
271
PHILIP W. HOWARD
CONTENTS TO VOLUME 2
PREFACE
X V
A PERSONAL FOREWORD
XIX
ACKNOWLEDGMENTS
XXI
PART IV PHYSIOLOGICAL AND MANUFACTURING CONSIDERATIONS FOR
BIOLOGIES
311
10 PHARMACOKINETICS OF THERAPEUTIC PROTEINS
313
ZHENG LU, JENNIFER SHENG, AND WENHUI ZHANG
10.1 ABSORPTION 313
10.2 DISTRIBUTION 315
10.3 METABOLISM AND ELIMINATION 316
10.3.1 FCRN-MEDIATED SALVAGE AND THE NONSPECIFIC (LINEAR) CLEARANCE 317
10.3.2 TARGET-MEDIATED DRUG DISPOSITION 318
10.3.3 IMMUNOGENICITY-INDUCED CLEARANCE CHANGE 320
10.3.4 FRAGMENT OF MABS 322
10.3.5 VARIABILITY 323
10.3.6 RENAL CLEARANCE OF MABS 324
10.4 PHARMACOKINETIC MODELING OF THERAPEUTIC PROTEINS 325
REFERENCES 334
11 SAFETY CONSIDERATIONS FOR BIOLOGIES
341
MAGGIE DEMPSTER, LUCINDA R. WEIR, AND RAJNIS. FAGG
11.1 INTRODUCTION 341
11.2 SMALL MOLECULES VERSUS LARGE MOLECULES - A COMPARISON 342
11.3 TOXICITY RELATED TO EXAGGERATED PHARMACOLOGY - IMPORTANCE OF
SPECIES SELECTION 344
11.4 TOXICITY UNRELATED TO EXAGGERATED PHARMACOLOGY 347
11.4.1 CYTOKINE STORM 347
11.4.2 UNEXPECTED TOXICITY 348
11.5 REGULATORY GUIDANCE 349
11.6 DEVELOPMENT CONSIDERATIONS DUE TO BIOLOGICAL CHARACTERISTICS 350
11.6.1 EARLY DISCOVERY - INFORMATION NEEDED TO SET THE STAGE AND EARLY
STUDIES 350
11.6.1.1 NEW TARGETS/PATHWAYS 350
11.6.1.2 ALTERNATE HIT/LEAD DISCOVERY APPROACHES FOR EXISTING TARGETS
352
11.6.1.3 NEW LEAD OPTIMIZATION METHODS 354
11.6.1.4 FEASIBILITY/TRACTABILITY ASSESSMENT 360
11.7 FIRST IN HUMAN (FIH) TO REGISTRATION 366
11.7.1 CROSS-REACTIVITY STUDY 366
11.7.2 SAFETY PHARMACOLOGY 367
11.7.3 IN VIVO STUDIES 367
11.7.4 SELECTION OF DOSE LEVELS 369
11.7.5 PHARMACOKINETICS/PHARMACODYNAMICS 369
11.7.6 IMMUNOGENICITY 370
11.7.7 IMMUNOTOXICITY 371
11.7.8 REPRODUCTIVE TOXICITY 371
11.7.8.1 FERTILITY 372
11.7.8.2 EMBRYOFETAL DEVELOPMENT AND PRE- AND POSTNATAL
DEVELOPMENT 372
11.7.9 GENOTOXICITY AND CARCINOGENICITY 374
11.8 SELECTION OF A SAFE STARTING DOSE FOR FIRST TIME IN HUMAN CLINICAL
STUDY 374
11.9 SUMMARY 375
REFERENCES 376
12 IMMUNOGENICITY OF BIOLOGIES
387
MATTHEW R BAKER; TIMOTHY D.
JONES, AND PAUL CHAMBERLAIN
12.1 INTRODUCTION 387
12.2 MECHANISTIC VIEW OF IMMUNOGENICITY: INNATE AND ADAPTIVE
IMMUNITY 388
12.2.1 INNATE IMMUNITY 388
12.2.1.1 DENDRITIC CELLS 388
12.2.1.2 ENDOCYTOSIS OF PROTEINS BY DC 390
12.2.1.3 INNATE IMMUNE RECEPTORS 391
12.2.2 ADAPTIVE IMMUNITY 393
12.2.2.1 ANTIGEN PROCESSING 393
12.2.2.2 T-CELL RECOGNITION OF MHC - PEPTIDE COMPLEXES 397
12.2.2.3 IMMUNOGENICITY RISK MITIGATION BY PROTEIN ENGINEERING 398
12.2.2.4 IMMUNOGENICITY AND THE PROPERTIES OF ANTIGENS 399
12.2.2.5 IMMUNOLOGICAL TOLERANCE 400
12.3 IMMUNOGENICITY OF PROTEIN THERAPEUTICS IN AUTOLOGOUS CELL
THERAPIES 402
12.4 REGULATORY CONTEXT 403
12.5 APPLICATION OF THE *RISK-BASED APPROACH* FOR UNDESIRABLE
IMMUNOGENICITY 405
12.5.1 LINKAGE TO PRODUCT LIFE CYCLE 405
12.5.2 INITIAL RISK ASSESSMENT FOR LEAD CANDIDATE SELECTION 405
12.5.3 EARLY SCREENING TO IDENTIFY *CRYPTIC* B-CELL EPITOPES 406
12.5.4 CONTROL OF PRODUCT QUALITY 407
12.5.5 IND-ENABLING SAFETY STUDIES 408
12.5.6 FIRST-TIME-IN-HUMAN STUDIES 409
12.6 CLINICAL PROOF OF CONCEPT AND BEYOND 410
12.7 FUTURE PERSPECTIVES 411
REFERENCES 411
13 EXPRESSION SYSTEMS FOR RECOMBINANT BIOPHARMACEUTICAL PRODUCTION
BY MAMMALIAN CELLS IN CULTURE
423
ADAM 1 BROWN, DEVIKA KALSI, ALEJANDRO FERNANDEZ-MARTELL, JOE CARTWRIGHT,
NICHOLAS
0.1
N. BARBER, YASH D. PATEL, RICHARD TURNER, CLAIRE L BRYANT, YUSUF B.
JOHARI, AND DAVID
C.
JAMES
13.1 INTRODUCTION 423
13.2 HOST CELL SYSTEMS 425
13.2.1 CHINESE HAMSTER OVARY (CHO) CELLS 425
13.2.2 ALTERNATIVE MAMMALIAN CELL HOSTS 428
13.2.3 NON-MAMMALIAN EXPRESSION SYSTEMS 428
13.3 MAMMALIAN CELL TRANSFECTION 430
13.3.1 METHODOLOGIES 430
13.3.2 BIOPROCESS APPLICATION 431
13.3.3 GENE TARGETING 432
13.4 CONTROLLING RECOMBINANT GENE EXPRESSION 433
13.4.1 INTRODUCTION 433
13.4.2 PROMOTERS 434
13.4.3 UNTRANSLATED REGIONS, EPIGENETIC REGULATORY ELEMENTS, AND
PROTEIN-CODING SEQUENCES 435
13.4.3.1 UNTRANSLATED REGIONS 435
13.4.3.2 EPIGENETIC REGULATORY ELEMENTS 436
13.4.3.3 PROTEIN-CODING SEQUENCES 437
13.5 SELECTION AND AMPLIFICATION SYSTEMS 437
13.6 TRANSIENT PRODUCTION SYSTEMS 438
13.6.1 CHO CELL ENGINEERING FOR INCREASED TRANSIENT PRODUCTION 439
13.6.2 RECOMBINANT DNA DELIVERY MECHANISMS 439
13.6.3 PROCESS AND MEDIA OPTIMIZATION 440
13.7 PROTEIN PURIFICATION 440
13.7.1 CLARIFICATION 441
13.7.2 CHROMATOGRAPHY 441
13.7.2.1 AFFINITY CHROMATOGRAPHY 441
13.7.2.2 ION-EXCHANGE CHROMATOGRAPHY 442
13.7.2.3 HYDROPHOBIC INTERACTION CHROMATOGRAPHY 443
13.7.2.4
13.7.3
13.7.4
13.7.5
13.8
13.8.1
13.8.2
13.8.3
13.8.4
13.8.5
13.8.6
13.8.7
13.8.8
14
14.1
14.2
14.3
14.3.1
14.3.2
14.3.2.1
14.3.3
14.3.3.1
14.3.3.2
14.3.3.3
14.3.3.4
14.4
14.5
15
15.1
15.2
15.2.1
15.2.2
15.2.3
15.2.4
MIXED-MODE CHROMATOGRAPHY 443
MEMBRANES 443
ECONOMICS 444
FUTURE TRENDS AND CONCLUSIONS 445
CHO CELL ENGINEERING FOR ENHANCED BIOPROCESSING
PROPERTIES 445
PROGRAMMED CELL DEATH 446
FOLDING AND ASSEMBLY MACHINERY 446
UNFOLDED PROTEIN RESPONSE 447
SECRETORY PATHWAY 447
GLYCOSYLATION PATHWAYS 447
GENE EDITING 449
DIRECTED EVOLUTION APPROACH 449
MIRNAS - A NOVEL CELL ENGINEERING APPROACH 450
ABBREVIATIONS 450
REFERENCES 452
STABILITY, FORMULATION, AND DELIVERY OF BIOPHARMACEUTICALS
469
HANNS-CHRISTIAN MAHLER AND ANDREA ALLMENDINGER
INTRODUCTION 469
STABILITY 469
DRUG PRODUCT DEVELOPMENT 471
PRODUCT REQUIREMENTS 472
CONTAINER CLOSURE SYSTEM (CCS) 473
SOME CHALLENGES WITH CONTAINER CLOSURE SYSTEMS 473
DEVELOPMENT OF THE PROTEIN FORMULATION 475
DOSAGE FORM 475
FORMULATION COMPOSITION 476
STABILITY TESTING 480
ANALYTICAL METHOD PANEL 482
HANDLING AND ADMINISTRATION CONSIDERATIONS 484
SUMMARY AND CONCLUSION 487
REFERENCES 487
PART V CLINICAL APPLICATIONS
493
PROTEIN THERAPEUTICS IN AUTOIMMUNE AND INFLAMMATORY
DISEASES
495
ANTHONY1 COYLE AND LEIGH 5.
ZAWEL
INTRODUCTION 495
RHEUMATOID ARTHRITIS 495
TNF-OC ANTAGONISTS 496
INHIBITION OF CO-STIMULATION 497
ANTI-IE-1 BASED THERAPIES 498
ANTI-IE-6 THERAPIES 498
15.2.5 B-CELL DEPLETION THERAPIES 499
15.3 PSORIASIS 500
15.4 TNF-OE ANTAGONIST THERAPY 500
15.5 ANTI-IL-12/IL-23 THERAPIES 501
15.6 ANTI-IL-17 THERAPIES 502
15.7 ATOPIE DERMATITIS 502
15.7.1 ANTI-IL-4/IL-13 THERAPIES 503
15.8 INFLAMMATORY BOWEL DISEASE (IBD) 503
15.8.1 PATHOPHYSIOLOGY OF IBD 504
15.8.2 ANTI-TNF-CC THERAPIES IN IBD 505
15.8.3 INTEGRIN INHIBITORS 506
15.8.4 IL-12/IL-23 THERAPIES 507
15.9 SYSTEMIC LUPUS ERYTHEMATOSUS 507
15.9.1 B-CELL-DIRECTED THERAPIES 508
15.9.1.1 RITUXIMAB 508
15.9.1.2 EPRATUZUMAB 508
15.9.1.3 BELIMUMAB 509
15.9.1.4 OTHER REGULATORS OF B CELLS SURVIVAL 509
15.9.2 TYPE I INTERFERONS AND SEE 510
15.10 CONCLUSIONS 511
REFERENCES 511
16 ANTIBODY-BASED THERAPEUTICS IN ONCOLOGY
521
PAUL A. MOORE, ROSS LA MOTTE-MOHS, JONATHAN C. LI,
AND GURUNADH R. CHICHILI
16.1 INTRODUCTION 521
16.2 TARGETING CELL-SURFACE SIGNALING PATHWAYS
IN SOLID TUMORS 522
16.2.1 ANTIBODY TARGETING OF RECEPTOR TYROSINE KINASES (RTKS)
PATHWAYS 522
16.2.1.1 ERBB FAMILY 522
16.2.1.2 EGER 529
16.2.1.3 HER2 530
16.2.1.4 HER3 531
16.2.1.5 INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) 532
16.2.1.6 PDGFR - PDGFROC 532
16.2.1.7 KIT FAMILY - COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) AND
KIT 533
16.2.1.8 VEGFR FAMILY - VEGFR1, VEGFR2, AND VEGFR3 533
16.2.1.9 VEGFR1 534
16.2.1.10 VEGFR2 534
16.2.1.11 VEGFR3 534
16.2.1.12 FGFR FAMILY - FGFR2, FGFR2B, AND FGFR3 535
16.2.1.13 HGFR FAMILY - PROTO-ONCOGENEC-MET (MET) AND RECEPTEUR
D*ORIGINE NANTAIS (RON) 535
16.2.1.14
16.2.2
16.2.2.1
16.2.2.2
16.2.2.3
16.2.2.4
16.3
16.3.1
16.3.2
16.3.2.1
16.3.2.2
16.3.2.3
16.3.3
16.4
16.4.1
16.4.1.1
16.4.1.2
16.4.1.3
16.4.2
16.5
17
17.1
17.2
17.2.1
17.2.2
17.2.3
17.2.4
17.3
17.3.1
17.3.2
17.4
17.5
17.5.1
17.5.2
17.5.3
17.6
17.7
EPHR FAMILY 536
TARGETING OF ADDITIONAL SIGNALING PATHWAYS AND CELL-SURFACE
ANTIGENS 537
NOTCH SIGNALING PATHWAY 537
WNT - FZD PATHWAY 538
DEATH RECEPTORS - TRAILR1 AND TRAILR2 538
ADDITIONAL CELL-SURFACE ANTIGENS 539
TARGETING OF IMMUNE MODULATORS 540
TUMOR IMMUNOLOGY 540
CHECK-POINT INHIBITORS 542
CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 (CTLA-4) 542
PROGRAMMED DEATH-1 (PD-1) AND PD-1 LIGAND 545
TARGETING OF ADDITIONAL PUTATIVE CHECK-POINT INHIBITOR
PATHWAYS 548
CO-STIMULATORY PATHWAYS 552
BISPECIFIC ANTIBODIES 557
IMMUNE CELL RE-TARGETING 558
LYMPHOID EFFECTORS 558
HEMATOLOGICAL MALIGNANCIES 561
SOLID TUMORS 563
DUAL TARGETING OF TWO RECEPTOR PATHWAYS ON CANCER CELL USING
BSABS 566
CONCLUSIONS AND FUTURE DIRECTIONS 568
REFERENCES 570
PROTEIN THERAPEUTICS IN RESPIRATORY MEDICINE
587
RAHUL SHRIMANKER AND IAN D. PAVORD
INTRODUCTION 587
ASTHMA 588
PHENOTYPES OF ASTHMA 590
BIOMARKERS 591
THE THL PATHWAY 593
THE TH2 PATHWAY 594
TH2-TARGETED THERAPIES 595
IMMUNOGLOBULIN E 595
INTERLEUKIN 5 597
MEPOLIZUMAB 597
OTHER ANTI-IL-5-TARGETED TREATMENTS 600
INTERLEUKIN 4 602
INTERLEUKIN 13 604
INTERLEUKIN 9 606
OTHER RESPIRATORY USES OF MONOCLONAL ANTIBODIES 606
SUMMARY 607
REFERENCES 608
18 ANTIBODIES FOR THE PREVENTION, TREATMENT, AND PREEMPTION OF
INFECTIOUS DISEASES
611
STEVE PROJAN
18.1 PROPHYLAXIS AND PRECISION MEDICINE 611
18.2 ANTIBACTERIAL IMMUNE THERAPY - A NINETEENTH CENTURY
BREAKTHROUGH 612
18.2.1 WHY HAS IT TAKEN SO LONG FOR NOVEL
IMMUNOTHERAPEUTICS? 612
18.2.2 MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF VIRAL
INFECTIONS 613
18.2.3 S. AUREUS: NO LONGER THE HOSPITAL SCOURGE? 614
18.2.4 MONOCLONAL ANTIBODIES TO PREVENT, TREAT OR PREEMPT STAPHYLOCOCCAL
INFECTIONS 614
18.2.5 R AERUGINOSA: THE BACTERIAL COCKROACH 615
18.2.6 IMMUNE EVASION: A BRIDGE TOO FAR? 616
18.2.7 MONOCLONAL ANTIBODIES FOR C. DIFFICILE
INFECTION: A WINNING BET OR A
CRAP SHOOT* 616
18.2.8 ARE TWO ANTIBODIES ENOUGH; IS SIX TOO MANY? 617
18.2.9 PROPHYLAXIS OR TREATMENT? BEWARE OF FALSE DICHOTOMIES 617
18.3 OTHER POTENTIAL ANTI-INFECTIVE MABS 617
18.3.1 SAFETY: HUMAN ENOUGH FOR YOU? 617
18.3.2 ANOTHER PRECINCT IS HEARD FROM: IMMUNOMODULATORY AGENTS FOR THE
TREATMENT OF CHRONIC INFECTIONS 618
18.3.3 ARE WE THERE YET? EASY-TO-USE, FAST-TURNAROUND, POINT-OF-CARE
DIAGNOSTICS 618
18.3.4 ARE BIOLOGIC DRUGS GOING TO BE TOO EXPENSIVE TO TREAT
INFECTIONS? 619
REFERENCES 619
19 RESCUE THERAPIES
621
STEPHAN GLUND AND MONIKA KROEZ
19.1 INTRODUCTION 621
19.1.1 CLINICAL DEVELOPMENT PECULIARITIES 621
19.2 ANTIDOTES/REVERSAL AGENTS 622
19.2.1 INTRODUCTION 622
19.2.2 ANTI-DIGOXIN FAB 622
19.2.2.1 BACKGROUND 622
19.2.2.2 MODE OF ACTION 623
19.2.2.3 STUDIES IN VOLUNTEERS 624
19.2.2.4 DOSE CONSIDERATIONS 624
19.2.2.5 COST CONSIDERATIONS 624
19.2.2.6 STUDIES IN PATIENTS 625
19.2.2.7 SAFETY 625
19.2.3 IDARUCIZUMAB AND ANDEXANET ALFA: REVERSAL AGENTS FOR ORAL
ANTICOAGULANTS 625
19.2.3.1 BACKGROUND 625
19.2.3.2 IDARUCIZUMAB 626
19.2.3.3 ANDEXANET ALFA 628
19.2.4 GLUCARPIDASE 629
19.2.4.1 BACKGROUND 629
19.2.4.2 MODE OF ACTION 629
19.2.4.3 STUDIES IN VOLUNTEERS 630
19.2.4.4 STUDIES IN PATIENTS 630
19.2.4.5 SAFETY 630
19.2.4.6 IMMUNOGENICITY 631
19.2.5 SELECTED REVERSAL-AGENT APPROACHES IN CLINICAL TESTING 631
19.2.5.1 BUTYRYLCHOLINESTERASE (PROTEXIA; TV-1380) 631
19.2.5.2 ANTI-METHAMPHETAMINE ANTIBODIES 631
19.3 ANTIVENOMS AND ANTITOXINS 631
19.3.1 BACKGROUND AND HISTORY 632
19.3.2 EPIDEMIOLOGY OF ENVENOMING 633
19.3.2.1 EFFECTS OF IMMUNOGLOBULIN DESIGN ON ANTISERUM
PHARMACOKINETICS 633
19.3.3 GENERATION OF ANTIVENOMS AND ANTITOXINS 634
19.3.4 SPECIFICITY 635
19.3.4.1 ANTI-ANTHRAX APPROACHES 635
19.3.5 SAFETY AND TOLERABILITY 637
19.4 CONCLUSION 638
REFERENCES 638
20 BIOSIMILARS
645
JUN WANG
20.1 INTRODUCTION 645
20.2 CONCEPT AND DEFINITION OF BIOSIMILARS 645
20.2.1 GENERIC SMALL MOLECULE DRUGS COMPARED WITH BIOSIMILARS 645
20.2.2 DEFINITION AND INTERPRETATION OF BIOSIMILARS 647
20.3 RATIONALE AND SIGNIFICANCE OF BIOSIMILARS 648
20.3.1 THE POTENTIAL FOR COST REDUCTION 648
20.3.2 THE SCALE OF THE OPPORTUNITY TO REDUCE COST 650
20.4 CURRENT APPROVALS AND TRENDS 651
20.4.1 BIOSIMILAR APPROVALS 651
20.4.2 REGULATORY PATHWAYS FOR BIOSIMILARS 653
20.4.2.1 QUALITY 654
20.4.2.2 NON-CLINICAL AND CLINICAL STUDIES 655
20.5 CHALLENGES AND FUTURE TRENDS 656
REFERENCES 658
PART VI FUTURE HORIZONS
661
21 FUTURE HORIZONS AND NEW TARGET CLASS OPPORTUNITIES
663
HERREN WU, CARL WEBSTER, JUDY PATERSON, SANDRINE GUILLARD, RON JACKSON,
AND
RALPH M INTER
21.1 INTRODUCTION 663
21.2 TARGETING THE CENTRAL NERVOUS SYSTEM 663
21.2.1 THE OPPORTUNITY 663
21.2.2 THE CHALLENGE 664
21.2.3 NATURES SOLUTION 665
21.2.4 TARGETING PATHWAYS INTO THE BRAIN 666
21.2.5 LESSONS FROM PRECLINICAL STUDIES 669
21.2.6 ADME IN THE BRAIN 670
21.2.7 PATH TO THE CLINIC 671
21.2.8 FUTURE PERSPECTIVES 671
21.3 INTRACELLULAR BIOLOGIES 672
21.3.1 THE OPPORTUNITY FOR INTRACELLULAR BIOLOGIES 672
21.3.2 THE CHALLENGES OF INTRACELLULAR DELIVERY 672
21.3.3 NATURES SOLUTION TO THE CHALLENGES OF INTRACELLULAR DELIVERY: AB
TOXINS 674
21.3.4 RE-ENGINEERING AB TOXINS FOR NOVEL THERAPEUTIC FUNCTIONS 675
21.3.5 ALTERNATIVE DELIVERY STRATEGIES FOR INTRACELLULAR BIOLOGIES 677
21.3.6 INCREASING THE POTENCY OF INTRACELLULAR PAYLOADS 678
21.3.7 CONCLUSIONS AND OUTLOOK FOR INTRACELLULAR BIOLOGIES 679
21.4 BUILDING ON THE SUCCESS OF TRADITIONAL MONOCLONAL ANTIBODIES 679
21.4.1 RISE OF *NON-TRADITIONAL* ANTIBODIES 680
21.4.1.1 BISPECIFIC ANTIBODY AND MULTISPECIFIC BIOLOGIES 681
21.4.1.2 ANTIBODY-DRUG CONJUGATES 683
21.4.2 DAWN OF IN VIVO
EXPRESSED BIOLOGIES 684
21.4.3 ORAL BIOLOGIES 688
21.4.4 CONCLUSIONS 690
REFERENCES 690
INDEX
701
|
| any_adam_object | 1 |
| author2 | Vaughan, Tristan Osbourn, Jane Jallal, Bahija |
| author2_role | edt edt edt |
| author2_variant | t v tv j o jo b j bj |
| author_facet | Vaughan, Tristan Osbourn, Jane Jallal, Bahija |
| building | Verbundindex |
| bvnumber | BV044350036 |
| classification_rvk | VK 8560 VS 7000 VS 9400 |
| ctrlnum | (OCoLC)1012844540 (DE-599)DNB1140803662 |
| discipline | Chemie / Pharmazie |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01643nam a2200397 cc4500</leader><controlfield tag="001">BV044350036</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180315 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">170614s2017 gw a||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1140803662</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1012844540</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1140803662</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VK 8560</subfield><subfield code="0">(DE-625)147540:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 7000</subfield><subfield code="0">(DE-625)147697:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Protein therapeutics</subfield><subfield code="n">Volume 2</subfield><subfield code="c">edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim, Germany</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">[2017]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, Seiten 311-717</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">Volume 71b</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">volume 71</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaughan, Tristan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Osbourn, Jane</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jallal, Bahija</subfield><subfield code="4">edt</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="w">(DE-604)BV044349964</subfield><subfield code="g">2</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">Volume 71b</subfield><subfield code="w">(DE-604)BV035418617</subfield><subfield code="9">71,2</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">volume 71</subfield><subfield code="w">(DE-604)BV035418617</subfield><subfield code="9">71</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029752859&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029752859</subfield></datafield></record></collection> |
| id | DE-604.BV044350036 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:50:29Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029752859 |
| oclc_num | 1012844540 |
| open_access_boolean | |
| owner | DE-29 DE-11 DE-19 DE-BY-UBM |
| owner_facet | DE-29 DE-11 DE-19 DE-BY-UBM |
| physical | XXI, Seiten 311-717 Illustrationen, Diagramme |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | Wiley-VCH |
| record_format | marc |
| series | Methods and principles in medicinal chemistry |
| series2 | Methods and principles in medicinal chemistry |
| spelling | Protein therapeutics Volume 2 edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal Weinheim, Germany Wiley-VCH [2017] XXI, Seiten 311-717 Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Methods and principles in medicinal chemistry Volume 71b Methods and principles in medicinal chemistry volume 71 Vaughan, Tristan edt Osbourn, Jane edt Jallal, Bahija edt (DE-604)BV044349964 2 Methods and principles in medicinal chemistry Volume 71b (DE-604)BV035418617 71,2 Methods and principles in medicinal chemistry volume 71 (DE-604)BV035418617 71 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029752859&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Protein therapeutics Methods and principles in medicinal chemistry |
| title | Protein therapeutics |
| title_auth | Protein therapeutics |
| title_exact_search | Protein therapeutics |
| title_full | Protein therapeutics Volume 2 edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal |
| title_fullStr | Protein therapeutics Volume 2 edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal |
| title_full_unstemmed | Protein therapeutics Volume 2 edited by Tristan Vaughan, Jane Osbourn, and Bahija Jallal |
| title_short | Protein therapeutics |
| title_sort | protein therapeutics |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029752859&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV044349964 (DE-604)BV035418617 |
| work_keys_str_mv | AT vaughantristan proteintherapeuticsvolume2 AT osbournjane proteintherapeuticsvolume2 AT jallalbahija proteintherapeuticsvolume2 |